Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma

Masayuki Sasaki, Yasuo Kuwabara, Hirofumi Koga, Makoto Nakagawa, Tao Chen, Kouichirou Kaneko, Kazutaka Hayashi, Katsumasa Nakamura, Kouji Masuda

研究成果: ジャーナルへの寄稿記事

75 引用 (Scopus)

抄録

Objectives: The aim of this study is to evaluate the clinical impact of whole-body FDG-PET for the pre-therapeutic evaluation of malignant lymphoma and compared to that of 67Ga-scintigraphy when added to non-RI examinations. Methods: We examined 46 patients with malignant lymphoma including 42 newly diagnosed cases and 4 relapsed cases. Whole-body FDG-PET was started 63 minutes after the administration of FDG with ECAT EXACT HR+. The clinical stage of each patient was determined based on the results of a non-RI examination (consisting of physical examination, CT, gastrointestinal studies and bone marrow aspiration), 67Ga planar images and FDG-PET. Discrepant findings were verified based on the response to treatment and the findings of a follow-up examination more than 6 months after treatment. Finally, 152 nodal regions and 19 extranodal tissues were found to be involved by disease. Results: In the 152 nodal lesions, FDG-PET detected 54 nodal lesions in addition to 98 lesions detected by non-RI examinations, whereas 67Gascintigraphy detected 14 additional lesions. The sensitivity of non-RI, non-RI + 67Ga and non-RI + FDG was 64.5%, 73.7% and 100.0%, respectively. In 19 extranodal lesions, FDG-PET detected 5 extranodal lesions in addition to 13 lesions detected by non-RI examinations, whereas 67Gascintigraphy detected 1 additional lesion. The sensitivity of non-RI, non-RI + 67Ga and non-RI + FDG was 68.4%, 73.7% and 94.7%, respectively. When combining the FDG-PET findings with the non-RI findings, the improvement of the detectability was much higher than that when 67Ga findings were combined to the non-RI findings. For the staging of lymphoma, the non-RI and non-RI + 67Ga findings accurately diagnosed 76.1% and 80.4%, respectively, whereas the non-RI + FDG findings accurately diagnosed 82.6%. Finally, FDG-PET resulted in changes in the clinical management of 8 patients (17.4%). Conclusions: FDG-PET offers more information in addition to the findings of conventional diagnostic methods than 67Ga-scintigraphy in order to accurately detect malignant lymphoma. FDG-PET can therefore play an important role in therapeutic decision making on lymphoma.

元の言語英語
ページ(範囲)337-345
ページ数9
ジャーナルAnnals of Nuclear Medicine
16
発行部数5
DOI
出版物ステータス出版済み - 1 1 2002

Fingerprint

Lymphoma
Decision Making
Radionuclide Imaging
Therapeutics
Physical Examination
Bone Marrow

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

これを引用

Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma. / Sasaki, Masayuki; Kuwabara, Yasuo; Koga, Hirofumi; Nakagawa, Makoto; Chen, Tao; Kaneko, Kouichirou; Hayashi, Kazutaka; Nakamura, Katsumasa; Masuda, Kouji.

:: Annals of Nuclear Medicine, 巻 16, 番号 5, 01.01.2002, p. 337-345.

研究成果: ジャーナルへの寄稿記事

Sasaki, M, Kuwabara, Y, Koga, H, Nakagawa, M, Chen, T, Kaneko, K, Hayashi, K, Nakamura, K & Masuda, K 2002, 'Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma', Annals of Nuclear Medicine, 巻. 16, 番号 5, pp. 337-345. https://doi.org/10.1007/BF02988618
Sasaki, Masayuki ; Kuwabara, Yasuo ; Koga, Hirofumi ; Nakagawa, Makoto ; Chen, Tao ; Kaneko, Kouichirou ; Hayashi, Kazutaka ; Nakamura, Katsumasa ; Masuda, Kouji. / Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma. :: Annals of Nuclear Medicine. 2002 ; 巻 16, 番号 5. pp. 337-345.
@article{e2b3ed7c16df41f4a4de4fb15d717fcc,
title = "Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma",
abstract = "Objectives: The aim of this study is to evaluate the clinical impact of whole-body FDG-PET for the pre-therapeutic evaluation of malignant lymphoma and compared to that of 67Ga-scintigraphy when added to non-RI examinations. Methods: We examined 46 patients with malignant lymphoma including 42 newly diagnosed cases and 4 relapsed cases. Whole-body FDG-PET was started 63 minutes after the administration of FDG with ECAT EXACT HR+. The clinical stage of each patient was determined based on the results of a non-RI examination (consisting of physical examination, CT, gastrointestinal studies and bone marrow aspiration), 67Ga planar images and FDG-PET. Discrepant findings were verified based on the response to treatment and the findings of a follow-up examination more than 6 months after treatment. Finally, 152 nodal regions and 19 extranodal tissues were found to be involved by disease. Results: In the 152 nodal lesions, FDG-PET detected 54 nodal lesions in addition to 98 lesions detected by non-RI examinations, whereas 67Gascintigraphy detected 14 additional lesions. The sensitivity of non-RI, non-RI + 67Ga and non-RI + FDG was 64.5{\%}, 73.7{\%} and 100.0{\%}, respectively. In 19 extranodal lesions, FDG-PET detected 5 extranodal lesions in addition to 13 lesions detected by non-RI examinations, whereas 67Gascintigraphy detected 1 additional lesion. The sensitivity of non-RI, non-RI + 67Ga and non-RI + FDG was 68.4{\%}, 73.7{\%} and 94.7{\%}, respectively. When combining the FDG-PET findings with the non-RI findings, the improvement of the detectability was much higher than that when 67Ga findings were combined to the non-RI findings. For the staging of lymphoma, the non-RI and non-RI + 67Ga findings accurately diagnosed 76.1{\%} and 80.4{\%}, respectively, whereas the non-RI + FDG findings accurately diagnosed 82.6{\%}. Finally, FDG-PET resulted in changes in the clinical management of 8 patients (17.4{\%}). Conclusions: FDG-PET offers more information in addition to the findings of conventional diagnostic methods than 67Ga-scintigraphy in order to accurately detect malignant lymphoma. FDG-PET can therefore play an important role in therapeutic decision making on lymphoma.",
author = "Masayuki Sasaki and Yasuo Kuwabara and Hirofumi Koga and Makoto Nakagawa and Tao Chen and Kouichirou Kaneko and Kazutaka Hayashi and Katsumasa Nakamura and Kouji Masuda",
year = "2002",
month = "1",
day = "1",
doi = "10.1007/BF02988618",
language = "English",
volume = "16",
pages = "337--345",
journal = "Annals of Nuclear Medicine",
issn = "0914-7187",
publisher = "Springer Japan",
number = "5",

}

TY - JOUR

T1 - Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma

AU - Sasaki, Masayuki

AU - Kuwabara, Yasuo

AU - Koga, Hirofumi

AU - Nakagawa, Makoto

AU - Chen, Tao

AU - Kaneko, Kouichirou

AU - Hayashi, Kazutaka

AU - Nakamura, Katsumasa

AU - Masuda, Kouji

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Objectives: The aim of this study is to evaluate the clinical impact of whole-body FDG-PET for the pre-therapeutic evaluation of malignant lymphoma and compared to that of 67Ga-scintigraphy when added to non-RI examinations. Methods: We examined 46 patients with malignant lymphoma including 42 newly diagnosed cases and 4 relapsed cases. Whole-body FDG-PET was started 63 minutes after the administration of FDG with ECAT EXACT HR+. The clinical stage of each patient was determined based on the results of a non-RI examination (consisting of physical examination, CT, gastrointestinal studies and bone marrow aspiration), 67Ga planar images and FDG-PET. Discrepant findings were verified based on the response to treatment and the findings of a follow-up examination more than 6 months after treatment. Finally, 152 nodal regions and 19 extranodal tissues were found to be involved by disease. Results: In the 152 nodal lesions, FDG-PET detected 54 nodal lesions in addition to 98 lesions detected by non-RI examinations, whereas 67Gascintigraphy detected 14 additional lesions. The sensitivity of non-RI, non-RI + 67Ga and non-RI + FDG was 64.5%, 73.7% and 100.0%, respectively. In 19 extranodal lesions, FDG-PET detected 5 extranodal lesions in addition to 13 lesions detected by non-RI examinations, whereas 67Gascintigraphy detected 1 additional lesion. The sensitivity of non-RI, non-RI + 67Ga and non-RI + FDG was 68.4%, 73.7% and 94.7%, respectively. When combining the FDG-PET findings with the non-RI findings, the improvement of the detectability was much higher than that when 67Ga findings were combined to the non-RI findings. For the staging of lymphoma, the non-RI and non-RI + 67Ga findings accurately diagnosed 76.1% and 80.4%, respectively, whereas the non-RI + FDG findings accurately diagnosed 82.6%. Finally, FDG-PET resulted in changes in the clinical management of 8 patients (17.4%). Conclusions: FDG-PET offers more information in addition to the findings of conventional diagnostic methods than 67Ga-scintigraphy in order to accurately detect malignant lymphoma. FDG-PET can therefore play an important role in therapeutic decision making on lymphoma.

AB - Objectives: The aim of this study is to evaluate the clinical impact of whole-body FDG-PET for the pre-therapeutic evaluation of malignant lymphoma and compared to that of 67Ga-scintigraphy when added to non-RI examinations. Methods: We examined 46 patients with malignant lymphoma including 42 newly diagnosed cases and 4 relapsed cases. Whole-body FDG-PET was started 63 minutes after the administration of FDG with ECAT EXACT HR+. The clinical stage of each patient was determined based on the results of a non-RI examination (consisting of physical examination, CT, gastrointestinal studies and bone marrow aspiration), 67Ga planar images and FDG-PET. Discrepant findings were verified based on the response to treatment and the findings of a follow-up examination more than 6 months after treatment. Finally, 152 nodal regions and 19 extranodal tissues were found to be involved by disease. Results: In the 152 nodal lesions, FDG-PET detected 54 nodal lesions in addition to 98 lesions detected by non-RI examinations, whereas 67Gascintigraphy detected 14 additional lesions. The sensitivity of non-RI, non-RI + 67Ga and non-RI + FDG was 64.5%, 73.7% and 100.0%, respectively. In 19 extranodal lesions, FDG-PET detected 5 extranodal lesions in addition to 13 lesions detected by non-RI examinations, whereas 67Gascintigraphy detected 1 additional lesion. The sensitivity of non-RI, non-RI + 67Ga and non-RI + FDG was 68.4%, 73.7% and 94.7%, respectively. When combining the FDG-PET findings with the non-RI findings, the improvement of the detectability was much higher than that when 67Ga findings were combined to the non-RI findings. For the staging of lymphoma, the non-RI and non-RI + 67Ga findings accurately diagnosed 76.1% and 80.4%, respectively, whereas the non-RI + FDG findings accurately diagnosed 82.6%. Finally, FDG-PET resulted in changes in the clinical management of 8 patients (17.4%). Conclusions: FDG-PET offers more information in addition to the findings of conventional diagnostic methods than 67Ga-scintigraphy in order to accurately detect malignant lymphoma. FDG-PET can therefore play an important role in therapeutic decision making on lymphoma.

UR - http://www.scopus.com/inward/record.url?scp=0036655324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036655324&partnerID=8YFLogxK

U2 - 10.1007/BF02988618

DO - 10.1007/BF02988618

M3 - Article

C2 - 12230093

AN - SCOPUS:0036655324

VL - 16

SP - 337

EP - 345

JO - Annals of Nuclear Medicine

JF - Annals of Nuclear Medicine

SN - 0914-7187

IS - 5

ER -